

4-32634
Rec'd PCT/PTO 28 JUL 2005



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 306 148 B1**

(12)

EUROPEAN PATENT SPECIFICATION

- (43) Date of publication of patent specification: **12.01.94** (51) Int. Cl.⁵: **C07D 453/02, C07D 451/06, C07D 453/06, C07D 451/14, C07D 471/08, A61K 31/46, A61K 31/435, A61K 31/55**
- (21) Application number: **88307113.6**
- (22) Date of filing: **02.08.88**

(54) Azabicyclic ethers.

(30) Priority: **04.08.87 GB 8718444**
20.05.88 GB 8811975

(43) Date of publication of application:
08.03.89 Bulletin 89/10

(45) Publication of the grant of the patent:
12.01.94 Bulletin 94/02

(84) Designated Contracting States:
AT BE CH DE ES FR GR IT LI LU NL SE

(56) References cited:
EP-A- 0 149 088
US-A- 2 640 829

Basic Principles of Organic Chemistry, J.D. Roberts and M.C. Caserio, publ. by W.A. Benjamin Inc. 1965, New York, Amst., pp. 966-968, 979-982

The Structure and Reactions of Heterocyclic Compounds, M.H. Palmer, publ. by E. Arnold, Publishers Ltd., London 1967, preface and pp. 4,5,8,14,15

The Principles of Heterocyclic Chemistry, A.R. Katritzky and J.M. Lagowski, publ. by Methuen and Co. Ltd., London 1967, pp. ix-xvi and 2-5

(73) Proprietor: **JOHN WYETH & BROTHER LIMITED**
Huntercombe Lane South
Taplow
Maidenhead Berkshire, SL6 0PH(GB)

(72) Inventor: **Cliffe, Ian Anthony**
14 St Andrews Way
Cippenham Berks(GB)


(74) Representative: **Brown, Keith John Symons et al**
c/o Wyeth Laboratories
Huntercombe Lane South
Taplow Maidenhead Berkshire SL6 0PH. (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to ethers. In particular the invention relates to novel ethers, to processes for their preparation, their use and to pharmaceutical compositions containing them. The ethers are useful as antagonists of specific 5-hydroxytryptamine (5-HT) receptors as explained hereinbelow.

The novel ethers of the present invention are compounds of the general formula (I)



15 the heteroaromatic N-oxides of the compounds in which X is nitrogen; and the pharmaceutically acceptable acid addition salts of the compounds of formula I or the N-oxides, wherein




represents a heteroaryl group containing at least one hetero atom X selected from the group consisting of nitrogen, oxygen and sulphur and being optionally substituted by one or more groups selected from C₁-4-alkyl, C₁-4-alkoxy, amino, C₁-4-alkylamino, di(C₁-4-alkylamino), halogen, trifluoromethyl, phenyl, halophenyl, C₁-4-alkylphenyl, C₁-4-alkoxyphenyl, carboxy, carboxamido, nitro, thiol, C₁-4-alkylthio and C₁-4-alkoxycarbonyl; -B represents a saturated azabicyclic ring comprising from 7 to 11 ring carbon atoms and a ring nitrogen atom which is separated from the O atom of the ether linkage by 2 or 3 ring carbon atoms and where the ring nitrogen atom is not in the bridgehead position the N may be unsubstituted or substituted by a group R¹ where R¹ is C₁-6-alkyl, C₃-5-alkenyl, C₃-6-cycloalkyl, C₃-6-cycloalkyl-, C₁-2-alkyl or aryl- or heteroaryl-C₁-2-alkyl (where the aryl group is a phenyl or naphthyl radical optionally substituted by one or more halogen, C₁-4-alkoxy or C₁-4-alkyl groups and the heteroaryl group is a mono- or bicyclic heteroaryl radical containing one or two hetero atoms selected from oxygen, nitrogen and sulphur); and the -OB moiety is ortho to the hetero atom X; with the proviso that




40 is other than a substituted or unsubstituted isoquinolinyl radical and that when B represents a quinuclidyl or a tropanyl radical,



is other than a substituted or unsubstituted 2-pyridyl radical.
Compounds of formula I in which




55 represents 2-pyridyl optionally substituted by specified substituents and B represents a quinuclidyl or tropanyl radical are disclosed generically, and compounds in which




represents 6-chloropyrid-2-yl- and B represents tropan-3-yl or quinuclidyl are disclosed specifically, in GB 2152048A. The compounds are stated to have analgesic activity. The publication does not disclose 5-HT₃-antagonistic activity for the compounds. The compounds are excluded from the above scope.

Examples of heterocycles from which the heteroaryl radical



is derived include 5 membered heterocycles with one hetero atom (eg furan, pyrrole and thiophene) which may be ring fused to, for example, a benzene or cyclohexane ring (eg benzo(b)furan, benzo(c)furan, indole, benzothiophene); 5-membered heterocycles having two heteroatoms in 1,2 or 1,3-positions which may be ring fused to other rings (eg oxazoles, pyrazoles, imidazoles, thiazoles, benzimidazoles, benzoxazoles, purines); 5-membered heterocycles with three heteroatoms which may be ring fused to other rings (eg triazoles, benzotriazoles, oxadiazoles); 6-membered heterocycles with one heteroatom and which may be ring fused to other rings (eg pyridine, quinoline, phenanthrene, 5,6-cycloheptenopyridine, 5,6-cyclohexenopyridine); 6-membered heterocycles with two heteroatoms which may be ring fused to other rings (eg pyridazines, cinnolines, phthalazines, pyrazines, quinoxalines, pyrimidines, quinazolines); 6-membered heterocycles with three heteroatoms (eg 1,3,5-triazine) 7-membered heterocycles which may be fused to other rings (eg diazepines, benzodiazepines). In each example the heterocycles may optionally be substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄-alkyl)amino, halogen (preferably fluorine or chlorine), trifluoromethyl, phenyl, halophenyl, C₁₋₄ alkylphenyl, C₁₋₄-alkoxy phenyl, carboxy, carboxamido, nitro, thiol, C₁₋₄-alkylthio, C₁₋₄-alkoxycarbonyl.

Preferred




groups include 2-pyridyl optionally substituted by, for example, chloro, nitro, C₁₋₄-alkyl or carboxamido; 2- or 4- pyrimidyl optionally substituted by for example chloro, amino, C₁₋₄-alkoxy; 2-pyrazinyl optionally substituted by, for example, halo or C₁₋₄-alkyl; 2-pyridazinyl optionally substituted by, for example, halo or C₁₋₄-alkoxy; 2-quinolyl optionally substituted by C₁₋₄-alkyl; 2-thienyl; 2-benzo(b)thienyl; 1H-indazol-3-yl optionally substituted by, for example, nitro or C₁₋₄-alkyl; 2-benzoxazolyl; 2-benzothiazolyl; and 6-phenanthryl.

Particularly preferred groups are optionally substituted pyridazines and also the bicyclic groups specifically mentioned above.

Examples of the saturated azabicyclic ring B include groups of the following formulae

(a)



(II)


where n is 2,3 or 4 and R² is hydrogen or has the meaning given for R¹ above

(b)



(III)

(c)



(IV)

where R² has the meaning given above and m is 1, 2 or 3 and

(d)



(V)

where p is 0, 1 or 2.

The preferred group B is that of formula (II) particularly that in which n is 2 and that in which R² is C₁₋₄-alkyl, preferably methyl. The radical in which n is 2 and R² is methyl is known as tropan-3-yl.

The radical of formula (III) is known as quinuclidyl.


In the radical of formula (IV), preferably m is 2, and R² is preferably C₁₋₄-alkyl, particularly methyl.

In the radical of formula (V), p is preferably 1.

The groups of formulae (II) to (IV) may contain at least one asymmetric carbon atom so that the compounds of the invention can exist in different stereoisomeric forms. The compounds can, for example, exist as racemates or optically active forms. Furthermore radicals such as those of formulae (II) to (IV) can exist in two different configurations corresponding to the endo configuration as in tropine and the exo configuration as in pseudotropine. The endo configuration is preferred.

In the compounds of formula I, any alkyl group is preferably methyl, ethyl, propyl or butyl; any alkoxy group is preferably methoxy, ethoxy or propoxy; an alkenyl group is preferably allyl or methallyl; a cycloalkyl is preferably cyclopentyl or cyclohexyl; cycloalkyl-alkyl is preferably cyclopentylmethyl or cyclohexylmethyl; arylalkyl is preferably benzyl; and where the R¹ group contains a heteroaryl radical this may be any one of the heteroaryl groups mentioned above in connection with the


45



50 radical.

The compounds of the invention may be prepared by methods known for the preparation of ethers. For example, a compound of formula

55



(VI)

or a N-oxide thereof may be condensed with a compound of formula

Z¹-B (VII)

5 where



10

and B are as defined above and one of Z and Z¹ is hydroxy and the other is a leaving group such as halogen, C₁₋₆-alkylsulphonyloxy (eg methylsulphonyloxy) or arylsulphonyloxy where the aryl radical may be, for example, phenyl or naphthyl optionally substituted by C₁₋₄-alkyl (eg p-toluenesulphonyloxy). Preferably Z is a leaving group, particularly halogen, and Z¹ is hydroxy. The condensation may be carried out in presence of a condensing agent, particularly a basic condensing agent such as an alkali metal or alkaline earth metal hydroxide or carbonate, potassium or sodium hydride, phenyl- or an alkyl-lithium (eg butyllithium), an alkali metal amide (eg lithium diisopropylamide) or an organic base such as a tertiary amine, pyridine or piperidine. The condensation may be carried out in an organic solvent. The anion of the alcohol may be first prepared by reaction of the alcohol with a strong base and the anion may be subsequently be reacted with the second reactant containing the leaving group.

20

It will be realised that if either the reactant (VI) or (VII) contains groups that would be affected under the reaction conditions employed for the condensation reaction the group may be protected and the protecting group subsequently removed. For example hydroxy groups may be protected by formation of acetals or ethers (eg benzyl or silyl ethers) and amino groups may be protected by formation of urethanes or N-benzyl derivatives.

25

In addition, any substituent present in the final compound of formula (I) may be removed or replaced by another substituent using methods that are known in the art. For example a chloro substituent on the heteroaromatic ring may be removed by catalytic hydrogenation or an alkoxycarbonyl substituent may be reduced to hydroxymethyl.

30

The compounds of formula (I) in which X is nitrogen may be converted into their heteroaromatic N-oxides by methods known for analogous compounds. For example, the compounds of formula (I) may be oxidised eg in an inert solvent with a peracid (eg peracetic acid, perbenzoic acid or m-chloroperbenzoic acid), hydrogen peroxide, an alkali metal peroxide or an alkyl peroxide. Oxidation may give the di-oxide which may be subsequently reduced, eg with sulphur di-oxide, to the mono N-oxide of the nitrogen containing heteroaromatic ring.

35

The starting materials of formulae (VI) and (VII) are described in the literature or may be prepared by methods known for analogous compounds.

If in the processes described above the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base, an acid addition salt, particularly a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compound.

40

Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic and p-toluenesulphonic acids. The compounds of the present invention possess pharmacological activity. In particular they antagonise specific 5-hydroxytryptamine (5-HT) receptors in warm blooded animals. Specifically the compounds possess 5-HT₃ antagonistic activity and hence are of value in conditions where antagonism of 5-HT₃ receptors is desirable. 5-HT₃-antagonists are also termed "antagonists of neuronal" 5-hydroxytryptamine receptors" and "serotonin (5-hydroxytryptamine) M-receptor antagonists". Such compounds have been described as being useful inter alia in the treatment of migraine, emesis, anxiety, gastrointestinal disorders and as anti-psychotics.

50

The compound of the invention are tested for 5-HT₃ receptor antagonism in the isolated vagus nerve of the rat by a method based upon that of Ireland S.J. and Tyers M.B., Brit. J. Pharmacol., 1987, 90, 229-238. The procedure relies upon the ability of 5-HT to induce depolarization of neurones in the cervical vagus nerve by a direct action on 5-HT₃ receptors. A concentration-response curve to 5-HT induced depolarization is obtained and the antagonists are added to the bath containing the isolated nerve before repeating the 5-HT concentration-response curve. Antagonist potency is estimated for the 5-HT concentration ratios and expressed as an apparent pK_B value (where K_B is the antagonist dissociation constant). When tested by this

55

indicating

procedure endo-8-methyl-3-(2-quinolyloxy)-8-azabicyclo[3.2.1]octane, a representative compound of this invention, had a pK_B of 7.5.

The compounds of the invention are also tested for 5-HT₃ antagonistic activity in the isolated right atrium of the rabbit heart based upon the method of Fozard J.R., Naunyn-Schmiedeberg's Arch. Pharmacol., 1984, 326, 36-44. This procedure relies upon the ability of 5-HT to stimulate 5-HT₃ receptors present on sympathetic nerve terminals in the heart, causing release of noradrenaline which evokes an increase in the spontaneous rate of beating. The antagonist potency is expressed in a similar manner to that of the preceding test method ie as an apparent pK_B . When tested by this procedure endo-8-methyl-3-(2-quinolyloxy)-8-azabicyclo[3.2.1]octane, a representative compound of this invention, had a pK_B of 8.6.

The invention further provides a compound of formula (I) or its heteroaromatic N-oxide or a pharmaceutically acceptable acid addition salt thereof for use in antagonising 5-HT₃ receptors in a mammal.

The invention also provides a pharmaceutical composition comprising a compound of the invention in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In such a composition, the carrier is generally a solid or liquid or a mixture of a solid and a liquid.

Solid form compositions include powders, granules, tablets, capsules (eg hard and soft gelatin capsules), suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, eg from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.

Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions. The active ingredient, for example, can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above eg cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols eg glycerol and glycols) and their derivatives, and oils (eg fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilised by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.

The compounds of the invention can also be administered by the nasal route. When formulated for nasal administration the compositions may comprise a compound of the invention in a liquid carrier; such compositions may be administered for example in the form of a spray or as drops. The liquid carrier may be water (which may contain further components to provide the desired isotonicity and viscosity of the composition). The composition may also contain additional excipients such as preservatives, surface-active agents and the like. The compositions may be contained in a nasal applicator that enables the composition to be administered as drops or as a spray. For administration from an aerosol container the composition should also include a propellant.

Preferably the pharmaceutical composition is in unit dosage form, eg as tablets or capsules. In such form, the composition is sub-divided in unit doses containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in packaged form. The quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750

mg or more, according to the particular need and the activity of the active ingredient.

The following Examples illustrate the invention:

Example 1

Endo-8-methyl-3-(2-pyrimidyloxy)-8-azabicyclo[3.2.1]octane

A stirred solution of tropine (6 g, 42.5 mmol) in dry dimethyl sulphoxide (50 ml) was treated with sodium hydride, 50% dispersion in oil (2.3 g containing ca. 47.9 mmol sodium hydride) under nitrogen. After 30 min, the solution was treated with 2-chloropyrimidine (5.2 g, 45.4 mmol), and after 3 h treated with water (200 ml) and extracted with ethyl acetate (2 x 100 ml). The organic phases were combined and extracted with 0.25 N-HCl (200 ml). The aqueous extract was washed with ethyl acetate (2 x 200 ml), basified with sodium hydroxide and extracted with ethyl acetate (2 x 200 ml). The extracts were dried (magnesium sulphate) and evaporated in vacuo to give a yellow liquid. The liquid was converted into the hydrochloride salt with ethereal hydrogen chloride and methanol. The salt was recrystallised from ethyl acetate-methanol to give the title compound as the dihydrochloride (3.86 g), mp 205-207° (dec.) (Found: C,48.5; H,6.7; N,14.1. $C_{12}H_{17}N_3O \cdot 2HCl$ requires C,48.6; H,6.8; N,14.2%).

Example 2

Endo-8-methyl-3-(2-quinolyloxy)-8-aza-bicyclo[3.2.1]octane

A stirred solution of tropine (5.94g, 42.1 mmol) in dry dimethyl sulphoxide (40 ml) was treated with sodium hydride, 50% dispersion in oil (2.3g containing ca. 47.9 mmol sodium hydride) under nitrogen. After 30 min the solution was treated with 2-chloroquinoline (6.88 g, 42.1 mmol), and after 3 h treated with water (200 ml). The solution was extracted with ether (3 x 150 ml). The extracts were combined and extracted with 0.25 N-HCl (200 ml). The aqueous extract was washed with ether (200 ml), basified with 10 N-NaOH, and extracted with ethyl acetate (2 x 200 ml). The extracts were dried (magnesium sulphate) and evaporated in vacuo to give a yellow solid which was triturated with ether (10 ml). The solid was converted into the hydrochloride salt with ethereal hydrogen chloride and methanol. The salt was recrystallised from ethyl acetate-methanol to give the title compound as the dihydrochloride (4.1 g), m.p. 190-200° (dec). Found: C,59.3; H,6.7; N,7.85. $C_{17}H_{20}N_2O \cdot 2HCl$ requires C,59.8; H,6.5; N,8.2%).

Example 3

Endo-8-methyl-3-(2-pyrazinyloxy)-8-azabicyclo[3.2.1]octane

The above compound was prepared from tropine (9.09 g, 63.7 mmol), 2-chloropyrazine (7.33 g, 64.0 mmol), and sodium hydride, 50% dispersion in oil (3.4 g) using the method described in Example 1. The dihydrochloride salt was isolated as colourless crystals (8.75 g), m.p. 244-246° (dec) (from methanol-ethyl acetate) (Found: C,47.1; H,6.7; N,13.7. $C_{12}H_{17}N_3O \cdot 2HCl$. $\frac{1}{2}H_2O$ requires C,47.2; H,6.8; N,13.8%).

Example 4

Endo-3-(6-chloropyridazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

The above compound was prepared by the method described in Example 1. The reaction of tropine (6.0 g, 42.6 mmol), 3,6-dichloropyridazine (12.7 g, 85.2 mmol), and sodium hydride, 50% dispersion in oil (2.25 g) gave a brown solid which was purified by chromatography (alumina; ether). The dihydrochloride salt was isolated as colourless crystals (0.8 g), m.p. 181-184° (dec.) (from methanol-ethyl acetate) (Found: C,43.5; H,5.6; N, 13.1. $C_{12}H_{16}ClN_3O \cdot 2HCl$. $\frac{1}{4}H_2O$ requires C,43.5; H,5.6; N,12.7%).

Example 5Endo-3-(6-chloropyrazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

5 The compound was prepared from 2,6-dichloropyrazine (6.49 g, 43.6 mmol), tropine (5.58 g, 39.6 mmol) and sodium hydride, 50% dispersion in oil (2.1 g) by the method outlined in Example 1.

The product was converted to the hydrochloride salt and recrystallised from methanol-ethyl acetate to give the title compound as the hydrochloride (3.77 g), m.p. 275-277° (dec.)
(Found: C,49.7; H,5.8; N,14.6.)

10 $C_{12}H_{16}ClN_3O$. HCl required C,49.6; H,5.9; N,14.5%.

Example 6Endo-3-(benzothiazol-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

15 A stirred solution of tropine (6.10g, 43.3mmol) in dry dimethylsulphoxide (100ml) was treated with sodium hydride, 50% dispersion in oil (2.3g) under nitrogen. After 40 min, 2-chlorobenzothiazole (6.2ml, 47.7mmol) was added and, after 18h, the mixture was poured into water (400ml). The precipitate was filtered and recrystallised from ethyl acetate to give the title compound as yellow crystals.

20 The hydrochloride salt was isolated from ethyl acetate-methanol as white crystals (7.04g) m.p. 225 - 227° (dec.).

(Found: C,58.2; H,6.2; N,9.0. $C_{15}H_{18}N_2OS.HCl$ requires C,58.0; H,6.2; N,9.0%).

Example 7Endo-3-(pyridazin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

25 A solution of endo-3-(6-chloropyridazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane dihydrobromide (2.97 g, 7.3 mmol) in ethanol (250 ml) was treated with 33% w/w aqueous ammonia (50 ml), reduced with hydrogen at 50 p.s.i. using 10% palladium on charcoal (1.8 g) as catalyst, filtered, and evaporated in vacuo to dryness. The residue was azeotroped in vacuo with toluene (100 ml) and triturated with dichloromethane (200 ml). The triturates were dried ($MgSO_4$) and evaporated in vacuo to give a solid which was recrystallised from ethyl acetate - ethanol to give colourless crystals of the product (1.07 g).

The monohydrobromide salt of the product was prepared as colourless crystals, m.p. 223-227°

35 (Found: C,47.6; H,6.1; N,13.8)

$C_{12}H_{17}N_3O$. HBr requires C,48.0; H,6.0; N,14.0%.

Example 840 2-Quinoliny 3-quinuclidinyl ether

Sodium hydride, 80% dispersion in oil (1.11 g) was treated with dimethyl sulphoxide (100 ml) with stirring and iced water - bath cooling under a bubbler air-lock. 3-Quinuclidinol (4.227 g, 33.6 mmol) was added after 15 min and 2-chloroquinoline (6.05 g, 37.0 mmol) added after 45 min. The mixture was allowed to warm to room temperature and after 6 days poured into water (400 ml). The mixture was extracted with ethyl acetate (3 x 200 ml). The extracts were combined and extracted with 0.4 N-HCl (250 ml). The aqueous extract was washed with ethyl acetate (200 ml), basified with 2N-NaOH, and extracted with chloroform (3 x 200 ml). The organic extracts were dried ($MgSO_4$) and evaporated in vacuo to give a solid which was recrystallised from methanol-ethyl acetate to yield the product free base (3.14 g)

50 The dihydrochloride salt of the product was prepared in methanol with ethereal hydrogen chloride as colourless crystals.

(Found: C,51.55; H,6.6; N,7.2)

$C_{16}H_{18}N_2O.2HCl.2.5H_2O$ requires C,51.6; H,6.8; N,7.5%.

Example 9Endo-(phenanthrin-6-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

The title compound was prepared by the procedure given in Example 8 using 6-chlorophenanthrine (4.63g, 21.7 mmol), tropine (2.78g, 19.7 mmol), and sodium hydride, 80% dispersion in oil (0.65g, 21.7 mmol) in dimethyl sulphoxide (100ml). The crude product was purified by chromatography (alumina; ether). The dihydrochloride salt was prepared with ethereal hydrogen chloride and methanol as pale yellow crystals (2.55g), m.p. 215-235° (dec)

(Found: C, 62.3; H, 6.45; N, 6.8
 $C_{21}H_{22}N_2O_2HCl \frac{1}{4} H_2O$ requires
 C, 62.3; H, 6.35; N, 6.9%.)

Example 10Endo-3-(benzoxazol-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

A stirred solution of tropine (3.02g, 21.4 mmol) in dry tetrahydrofuran (40 ml) was treated dropwise with 1.48M-butyllithium in hexane (14.5ml) under an atmosphere of nitrogen. After the slight exotherm had subsided, 2-chlorobenzoxazole (2.5ml, 21.9 mmol) was added dropwise so that the temperature remained below 30°. After 1h, the solution was evaporated in vacuo and the residue treated with chloroform (150ml). The mixture was filtered and the filtrate evaporated in vacuo to give a yellow oil. The oil was purified by chromatography (alumina; ether) to give the product as colourless crystals (4.00g) m.p. 85-87° (Found: C, 69.5; H, 7.1; N, 10.9. $C_{15}H_{18}N_2O_2$ requires C, 69.7; H, 7.0; N, 10.8%)

Example 11Endo-18-methyl-3-(3-methyl-5,6-cyclohexenopyridin-2-yloxy)-8-azabicyclo[3.2.1]octane

This compound was prepared by the procedure given in Example 8 using 2-bromo-3-methyl-5,6-cyclohexenopyridine (8.36g, 37 mmol), tropine (4.75g, 33.6 mmol), and sodium hydride, 80% dispersion in oil (1.11g, 37 mmol) in dimethyl sulphoxide (100 ml). The crude product was purified by chromatography (alumina; di-iso-propyl ether) to give the product as a light yellow solid (0.97g,) m.p. 51-57°.

Example 12Endo-2-(8-methyl-8-azabicyclo[3.2.1]octan-3-yloxy)-5,6-cycloheptenopyridine-3-carboxylic acid ethyl ester

This compound was prepared by the procedure given in Example 8 using 2-bromo-5,6-cycloheptenopyridine-3-carboxylic acid ethyl ester (9.93 g, 33.3 mmol), tropine (4.28g, 30.3 mmol), and sodium hydride, 80% dispersion in oil (1g, 33.3 mmol) in dimethyl sulphoxide (100 ml). The crude product was purified by chromatography (alumina; ether) to give a colourless oil. The monohydrochloride salt of the product was prepared in methanol with ethereal hydrogen chloride and recrystallised from propan-2-ol- to give white crystals (0.59g), m.p. 234-239° (dec).

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, IT, LI, LU, NL, SE

(1.) A compound of general formula (I)



wherein



represents a heteroaryl group containing at least one hetero atom X selected from the group consisting of nitrogen, oxygen and sulphur; and being optionally substituted by one or more groups selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, amino, C₁₋₄-alkylamino, di(C₁₋₄-alkylamino), halogen, trifluoromethyl, phenyl, halophenyl, C₁₋₄-alkylphenyl, C₁₋₄-alkoxyphenyl, carboxy, carboxamido, nitro, thiol, C₁₋₄-alkylthio and C₁₋₄-alkoxycarbonyl; -B represents a saturated azabicyclic ring comprising from 7 to 11 ring carbon atoms and a ring nitrogen atom which is separated from the O atom of the ether linkage by 2 or 3 ring carbon atoms and where the ring nitrogen atom is not in the bridgehead position the N may be unsubstituted or substituted by a group R¹ where R¹ is C₁₋₆-alkyl, C₃₋₅-alkenyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl or aryl- or heteroaryl-C₁₋₂-alkyl (where the aryl group is a phenyl or naphthyl radical optionally substituted by one or more halogen, C₁₋₄-alkoxy or C₁₋₄-alkyl groups and the heteroaryl group is a mono- or bicyclic heteroaryl radical containing one or two hetero atoms selected from oxygen, nitrogen and sulphur); and the -OB moiety is ortho to the hetero atom X; with the proviso that



is other than a substituted or unsubstituted isoquinolinyl radical and that when B represents a quinclidyl or a tropanyl radical,




is other than a substituted or unsubstituted 2-pyridyl radical; or a heteroaromatic N-oxide of the compound in which X is nitrogen; or a pharmaceutically acceptable acid addition salt of the compound of formula I or the N-oxide.

2. A compound as claimed in claim 1 wherein


is 2-pyridyl optionally substituted by chloro, nitro, C₁₋₄-alkyl or carboxamido; 2- or 4- pyrimidyl optionally substituted by chloro, amino, C₁₋₄-alkoxy; 2-pyrazinyl optionally substituted by halo or C₁₋₄-alkyl; 2-pyridazinyl optionally substituted by halo or C₁₋₄-alkoxy; 2-quinolyl optionally substituted by C₁₋₄-alkyl; 2-thienyl; 2-benzo(b)thienyl; 1H-indazol-3-yl optionally substituted by nitro or C₁₋₄-alkyl; 2-benzoxazolyl; 2-benzothiazolyl; or 6-phenanthryl.

3. A compound as claimed in claim 1 or 2 wherein B is
(a)




(II)

where n is 2,3 or 4 and R² is hydrogen or has the meaning given for R¹ in claim 1,
(b)




(III),

(c)



(IV)

where R² has the meaning given above and m is 1, 2 or 3 or
(d)




(V)

where p is 0, 1 or 2.

4. A compound as claimed in claim 3 wherein B has the formula (II) in which n is 2 and R² is methyl.
5. A compound as claimed in claim 1 which is endo-8-methyl-3-(2-pyrimidyloxy)-8-azabicyclo[3.2.1]octane
or
endo-8-methyl-3-(2-quinolyloxy)-8-aza-bicyclo[3.2.1]octane
or
endo-8-methyl-3-(2-pyrazinyloxy)-8-azabicyclo[3.2.1]octane
or
endo-3-(6-chloropyridazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
or
endo-3-(6-chloropyrazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
or
endo-3-(benzothiazol-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
or
endo-3-(pyridazin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
or
2-quinoliny 3-quinuclidinyl ether
or
endo-(phenanthrin-6-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
or
endo-3-(benzoxazol-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
or
endo-8-methyl-3-(3-methyl-5,6-cyclohexenopyridin-2-yloxy)-8-azabicyclo[3.2.1]octane
or
endo-2-(8-methyl-8-azabicyclo[3.2.1]octan-3-yloxy)-5,6-cycloheptenopyridine-3-carboxylic acid ethyl ester; or a pharmaceutically acceptable salt thereof.
6. A method for the preparation of a compound claimed in claim 1 which comprises

(a) condensing a compound of formula



(VI)

or an N-oxide thereof, with a compound of formula

Z¹-B (VII)

where




and B are as defined in claim 1 and one of Z and Z¹ is hydroxy and the other is a leaving group or
 (b) replacing or removing a substituent on the heteroaryl group or the azabicyclic ring of a
 compound of formula (I) by methods known in the art to give another compound of formula I or
 (c) oxidising a compound of formula (I) to the heteroaromatic N-oxide thereof or
 (d) converting a compound of formula (I) or the heteroaromatic N-oxide thereof into its pharmaceuti-
 cally acceptable acid addition salt.

7. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 5 in association with a pharmaceutically acceptable carrier.
8. A compound as claimed in any one of claims 1 to 5 for use as a pharmaceutical.

Claims for the following Contracting States : ES, GR

1. A process for preparing a compound of general formula (I)



(I)

wherein



represents a heteroaryl group containing at least one hetero atom X selected from the group consisting of nitrogen, oxygen and sulphur; and being optionally substituted by one or more groups selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, amino, C₁₋₄-alkylamino, di(C₁₋₄-alkylamino), halogen, trifluoromethyl, phenyl, halophenyl, C₁₋₄-alkylphenyl, C₁₋₄-alkoxyphenyl, carboxy, carboxamido, nitro, thiol, C₁₋₄-alkylthio and C₁₋₄-alkoxycarbonyl; -B represents a saturated azabicyclic ring comprising from 7 to 11 ring carbon atoms and a ring nitrogen atom which is separated from the O atom of the ether linkage by 2 or 3 ring carbon atoms and where the ring nitrogen atom is not in the bridgehead position the N may be unsubstituted or substituted by a group R¹ where R¹ is C₁₋₆-alkyl, C₃₋₅-alkenyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl or aryl- or heteroaryl-C₁₋₂-alkyl (where the aryl group is a phenyl or naphthyl radical optionally substituted by one or more halogen, C₁₋₄-alkoxy or C₁₋₄-alkyl groups and the heteroaryl group is a mono- or bicyclic heteroaryl radical containing one or two hetero atoms selected from oxygen, nitrogen and sulphur); and the -OB moiety is ortho to the hetero atom X; with the proviso

that

5



is other than a substituted or unsubstituted isoquinolinyl radical and that when B represents a quinuclidyl or a tropanyl radical,

10




15

is other than a substituted or unsubstituted 2-pyridyl radical; or a heteroaromatic N-oxide of the compound in which X is nitrogen; or a pharmaceutically acceptable acid addition salt of the compound of formula I or the N-oxide, which comprises

(a) condensing a compound of formula

20



(VI)

25

or an N-oxide thereof, with a compound of formula

Z¹-B (VII)

30

where

35




and B are as defined above and one of Z and Z¹ is hydroxy and the other is a leaving group or (b) replacing or removing a substituent on the heteroaryl group or the azabicyclic ring of a compound of formula (I) by methods known in the art to give another compound of formula I or (c) oxidising a compound of formula (I) to the heteroaromatic N-oxide thereof or (d) converting a compound of formula (I) or the heteroaromatic N-oxide thereof into its pharmaceutically acceptable acid addition salt.

40

45 2. A process as claimed in claim 1 which comprises condensing a compound of formula (VI) in which Z is halogen with a compound of formula (VII) in which Z¹ is hydroxy.

3. A process as claimed in claim 1 or 2 wherein in the product

50




55

is 2-pyridyl optionally substituted by chloro, nitro, C₁₋₄-alkyl or carboxamido; 2- or 4- pyrimidyl optionally substituted by chloro, amino, C₁₋₄-alkoxy; 2-pyrazinyl optionally, substituted by halo or C₁₋₄-alkyl; 2-pyridazinyl optionally substituted by halo or C₁₋₄-alkoxy; 2-quinolyl

optionally substituted by C₁₋₄-alkyl; 2-thienyl; 2-benzo(b)thienyl; 1H-indazol-3-yl optionally substituted by nitro or C₁₋₄-alkyl; 2-benzoxazolyl; 2-benzothiazolyl; or 6-phenanthryl.

4. A process as claimed in any one of claims 1 to 3 wherein in the product B is

(a)



where n is 2,3 or 4 and R² is hydrogen or has the meaning given for R¹ in claim 1,

(b)



(c)



where R² has the meaning given above and m is 1, 2 or 3 or

(d)



where p is 0, 1 or 2.

5. A process as claimed in claim 4 wherein B has the formula (II) in which n is 2 and R² is methyl.

6. A process as claimed in claim 1 wherein the product is
 endo-8-methyl-3-(2-pyrimidyloxy)-8-azabicyclo[3.2.1]octane
 or
 endo-8-methyl-3-(2-quinolyloxy)-8-aza-bicyclo[3.2.1]octane
 or
 endo-8-methyl-3-(2-pyrazinyloxy)-8-azabicyclo[3.2.1]octane
 or
 endo-3-(6-chloropyridazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
 or
 endo-3-(6-chloropyrazin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
 or
 endo-3-(benzothiazol-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane
 or
 endo-3-(pyridazin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

or
2-quinoliny 3-quinuclidiny ether

or
endo-(phenanthrin-6-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

or
endo-3-(benzoxazol-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane

or
endo-8-methyl-3-(3-methyl-5,6-cyclohexenopyridin-2-yloxy)-8-azabicyclo[3.2.1]octane

or
endo-2-(8-methyl-8-azabicyclo[3.2.1]octan-3-yloxy)-5,6-cycloheptenopyridine-3-carboxylic acid ethyl ester;
or a pharmaceutically acceptable salt thereof.

7. A process for preparing a pharmaceutical composition which comprises bringing a compound of general formula (I) as defined in claim 1, or a heteroaromatic N-oxide of the compound in which X is nitrogen or a pharmaceutically acceptable acid addition salt of the compound of formula (I) or the N-oxide, into association with a pharmaceutically acceptable carrier.

8. A process as claimed in claim 7 wherein the active ingredient is prepared by the process claimed in any one of claims 1 to 6.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, IT, LI, LU, NL, SE

1. Verbindung der allgemeinen Formel (I)



worin



eine Heteroarylgruppe mit mindestens einem Heteroatom X ausgewählt aus der Gruppe bestehend aus Stickstoff, Sauerstoff und Schwefel und gegebenenfalls substituiert durch eine oder mehrere Gruppen ausgewählt aus C₁-C₄-Alkyl, C₁-C₄-Alkoxy, Amino, C₁-C₄-Alkylamino, Di(C₁-C₄-alkylamino), Halogen, Trifluormethyl, Phenyl, Halogenphenyl, C₁-C₄-Alkylphenyl, C₁-C₄-Alkoxyphenyl, Carboxy, Carboxamido, Nitro, Thiol, C₁-C₄-Alkylthio und C₁-C₄-Alkoxy-carbonyl ist; -B einen gesättigten azabicyclischen Ring mit 7 bis 11 Ringkohlenstoffatomen und einem Ringstickstoffatom, das vom O-Atom der Etherbindung durch 2 oder 3 Ringkohlenstoffatome getrennt ist, und, wenn das Ringstickstoffatom nicht in der Brückenkopfstellung ist, das N unsubstituiert oder durch eine Gruppe R¹ substituiert sein kann, wobei R¹ C₁-C₆-Alkyl, C₃-C₅-Alkenyl, C₃-C₆-Cycloalkyl, C₃-C₆-Cycloalkyl-C₁-C₂-alkyl oder Aryl -oder Heteroaryl-C₁-C₂-alkyl ist (wobei die Arylgruppe ein Phenyl- oder Naphthylrest ist, der gegebenenfalls ein- oder mehrfach durch Halogen, C₁-C₄-Alkoxy oder C₁-C₄-Alkyl substituiert ist, und die Heteroarylgruppe ein mono- oder bicyclischer Heteroarylrest mit einem oder zwei Heteroatomen ausgewählt aus Sauerstoff, Stickstoff und Schwefel ist), und die Gruppe -OB ortho zum Heteroatom X ist; mit der Maßgabe, daß



von einem substituierten oder unsubstituierten Isochinoolinylrest verschieden ist und daß, wenn B einen Chinuclidyl- oder Tropanylrest darstellt,

5



10

von einem substituierten oder unsubstituierten 2-Pyridylrest verschieden ist, oder ein heteroaromatisches N-Oxid der Verbindung, worin X Stickstoff ist, oder ein pharmazeutisch annehmbares Säureadditionssalz der Verbindung der Formel (I) oder des N-Oxids.

2. Verbindung nach Anspruch 1, worin

15



20


2-Pyridyl gegebenenfalls substituiert durch Chlor, Nitro, C₁-C₄-Alkyl oder Carboxamido; 2- oder 4-Pyrimidyl gegebenenfalls substituiert durch Chlor, Amino, C₁-C₄-Alkoxy; 2-Pyrazinyl gegebenenfalls substituiert durch Halogen oder C₁-C₄-Alkyl; 2-Pyridazinyl gegebenenfalls substituiert durch Halogen oder C₁-C₄-Alkoxy; 2-Chinolyl gegebenenfalls substituiert durch C₁-C₄-Alkyl; 2-Thienyl; 2-Benzo(b)-thienyl; 1H-Indazol-3-yl gegebenenfalls substituiert durch Nitro oder C₁-C₄-Alkyl; 2-Benzoxazolyl; 2-Benzothiazolyl oder 6-PhenanthrinyI ist.

25

3. Verbindung nach Anspruch 1 oder 2, worin B

(a)

30




(II),

35

worin n 2, 3 oder 4 ist und R² Wasserstoff ist oder die für R¹ in Anspruch 1 angegebene Bedeutung hat,

(b)

40




(III),

45

(c)

50




(IV),

55

worin R² die oben angegebene Bedeutung hat und m 1, 2 oder 3 ist, oder

(d)




(V),

worin p Null, 1 oder 2 ist, darstellt.

4. Verbindung nach Anspruch 3, worin B die Formel (II) aufweist, wobei n 2 ist und R^2 Methyl darstellt.

5. Verbindung nach Anspruch 1, die
- endo-8-Methyl-3-(2-pyrimidyloxy)-9-azabicyclo[3,2,1]octan,
 - endo-8-Methyl-3-(2-chinolyloxy)-8-azabicyclo[3,2,1]octan,
 - endo-8-Methyl-3-(2-pyrazinyloxy)-8-azabicyclo[3,2,1]octan,
 - endo-3-(6-Chlorpyridazin-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
 - endo-3-(6-Chlorpyrazin-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
 - endo-3-(Benzothiazol-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
 - endo-3-(Pyridazin-3-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
 - 2-Chinolinyl-3-chinuclidinylether,
 - endo-(Phenanthrin-6-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
 - endo-3-(benzothiazol-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
 - endo-8-Methyl-3-(3-methyl-5,6-cyclohexenopyridin-2-yloxy)-8-azabicyclo[3,2,1]octan,
 - endo-2-(8-Methyl-8-azabicyclo[3,2,1]octan-3-yloxy)-5,6-cycloheptenopyridin-3-carbonsäure-ethylester
- oder ein pharmazeutisch annehmbares Salz hiervon ist.

6. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, das umfaßt:
- (a) das Kondensieren einer Verbindung der Formel



(VI)

oder eines N-Oxids hiervon mit einer Verbindung der Formel

$Z^1 - B$ (VII),

worin



und B wie in Anspruch 1 definiert sind und eines von Z und Z^1 Hydroxy und das andere eine Abgangsgruppe ist, oder

(b) das Ersetzen oder Entfernen eines Substituenten an der Heteroarylgruppe oder des azabicyclischen Ringes einer Verbindung der Formel (I) durch bekannte Verfahren, wobei eine andere Verbindung der Formel (I) erhalten wird, oder

(c) das Oxidieren einer Verbindung der Formel (I) zum heteroaromatischen N-Oxid hiervon oder

(d) das Überführen einer Verbindung der Formel (I) oder des heteroaromatischen N-Oxids hiervon in das pharmazeutisch annehmbare Säureadditionssalz hiervon.

7. Pharmazeutische Zusammensetzung, die eine Verbindung nach einem der Ansprüche 1 bis 5 in Verbindung mit einem pharmazeutisch annehmbaren Träger umfaßt.
8. Verbindung nach einem der Ansprüche 1 bis 5 zur Verwendung als Pharmazeutikum.

5

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zum Herstellen einer Verbindung der allgemeinen Formel (I)

10



15

worin

20



25

30

35

eine Heteroarylgruppe mit mindestens einem Heteroatom X ausgewählt aus der Gruppe bestehend aus Stickstoff, Sauerstoff und Schwefel und gegebenenfalls substituiert durch eine oder mehrere Gruppen ausgewählt aus C₁-C₄-Alkyl, C₁-C₄-Alkoxy, Amino, C₁-C₄-Alkylamino, Di(C₁-C₄-alkylamino), Halogen, Trifluormethyl, Phenyl, Halogenphenyl, C₁-C₄-Alkylphenyl, C₁-C₄-Alkoxyphenyl, Carboxy, Carboxamido, Nitro, Thiol, C₁-C₄-Alkylthio und C₁-C₄-Alkoxy-carbonyl ist; -B einen gesättigten azabicyclischen Ring mit 7 bis 11 Ringkohlenstoffatomen und einem Ringstickstoffatom, das vom O-Atom der Etherbindung durch 2 oder 3 Ringkohlenstoffatome getrennt ist, und, wenn das Ringstickstoffatom nicht in der Brückenkopfstellung ist, das N unsubstituiert oder durch eine Gruppe R¹ substituiert sein kann, wobei R¹ C₁-C₆-Alkyl, C₃-C₅-Alkenyl, C₃-C₆-Cycloalkyl, C₃-C₆-Cycloalkyl-C₁-C₂-alkyl oder Aryl- oder Heteroaryl-C₁-C₂-alkyl ist (wobei die Arylgruppe ein Phenyl- oder Naphthylrest ist, der gegebenenfalls ein- oder mehrfach durch Halogen, C₁-C₄-Alkoxy oder C₁-C₄-Alkyl substituiert ist, und die Heteroarylgruppe ein mono- oder bicyclischer Heteroarylrest mit einem oder zwei Heteroatomen ausgewählt aus Sauerstoff, Stickstoff und Schwefel ist), und die Gruppe -OB ortho zum Heteroatom X ist; mit der Maßgabe, daß

40



45

von einem substituierten oder unsubstituierten Isochinolinyrest verschieden ist und daß, wenn B einen Chinuclidyl- oder Tropanylrest darstellt,


50



55

von einem substituierten oder unsubstituierten 2-Pyridylrest verschieden ist, oder eines heteroaromatischen N-Oxids der Verbindung, worin X Stickstoff ist, oder eines pharmazeutisch annehmbaren Säureadditionssalzes der Verbindung der Formel (I) oder des N-Oxids, das umfaßt:

(a) das Kondensieren einer Verbindung der Formel




(VI)

oder eines N-Oxids hievon mit einer Verbindung der Formel

Z' - B (VII),

worin



und B wie oben definiert sind und eines von Z und Z' Hydroxy und das andere eine Abgangsgruppe ist, oder

(b) das Ersetzen oder Entfernen eines Substituenten an der Heteroarylgruppe oder des azabicyclischen Ringes einer Verbindung der Formel (I) durch bekannte Verfahren, wobei eine andere Verbindung der Formel (I) erhalten wird, oder

(c) das Oxidieren einer Verbindung der Formel (I) zum heteroaromatischen N-Oxid hievon oder

(d) das Überführen einer Verbindung der Formel (I) oder des heteroaromatischen N-Oxids hievon in das pharmazeutisch annehmbare Säureadditionssalz hievon.

2. Verfahren nach Anspruch 1, das das Kondensieren einer Verbindung der Formel (VI), worin Z Halogen ist, mit einer Verbindung der Formel (VII), worin Z' Hydroxy darstellt, umfaßt.


3. Verfahren nach Anspruch 1 oder 2, wobei im Produkt



2-Pyridyl gegebenenfalls substituiert durch Chlor, Nitro, C₁-C₄-Alkyl oder Carboxamido; 2- oder 4-Pyrimidyl gegebenenfalls substituiert durch Chlor, Amino, C₁-C₄-Alkoxy; 2-Pyrazinyl gegebenenfalls substituiert durch Halogen oder C₁-C₄-Alkyl; 2-Pyridazinyl gegebenenfalls substituiert durch Halogen oder C₁-C₄-Alkoxy; 2-Chinolyl gegebenenfalls substituiert durch C₁-C₄-Alkyl; 2-Thienyl; 2-Benzo(b)-thienyl; 1H-Indazol-3-yl gegebenenfalls substituiert durch Nitro oder C₁-C₄-Alkyl; 2-Benzoxazolyl; 2-Benzothiazolyl und 6-Phenanthryl ist.

4. Verfahren nach einem der Ansprüche 1 bis 3, wobei im Produkt B


(a)



(II),


worin n 2, 3 oder 4 ist und R² Wasserstoff ist oder die für R¹ in Anspruch 1 angegebene Bedeutung hat,

(b)




(III),

(c)



(IV),

worin R^2 die oben angegebene Bedeutung hat und m 1, 2 oder 3 ist, oder
(d)



(V),

worin p Null, 1 oder 2 ist, darstellt.

5. Verfahren nach Anspruch 4, wobei B die Formel (II) aufweist, in der n 2 ist und R^2 Methyl darstellt.

6. Verfahren nach Anspruch 1, bei dem das Produkt
endo-8-Methyl-3-(2-pyrimidyloxy)-8-azabicyclo[3,2,1]octan,
endo-8-Methyl-3-(2-chinolyloxy)-8-azabicyclo[3,2,1]octan,
endo-8-Methyl-3-(2-pyrazinyloxy)-8-azabicyclo[3,2,1]octan,
endo-3-(6-Chlorpyridazin-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
endo-3-(6-Chlorpyrazin-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
endo-3-(Benzothiazol-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
endo-3-(Pyridazin-3-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
2-Chinolinyl-3-chinuclidinylether,
endo-(Phenanthrin-6-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
endo-3-(Benzoxazol-2-yloxy)-8-methyl-8-azabicyclo[3,2,1]octan,
endo-8-Methyl-3-(3-methyl-5,6-cyclohexenopyridin-2-yloxy)-8-azabicyclo[3,2,1]octan,
endo-2-(8-Methyl-8-azabicyclo[3,2,1]octan-3-yloxy)-5,6-cycloheptenopyridin-3-carbonsäure-ethylester
oder ein pharmazeutisch annehmbares Salz hiervon ist.


7. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung, das das Vereinigen einer Verbindung der allgemeinen Formel (I), wie in Anspruch 1 definiert, oder eines heteroaromatischen N-Oxids der Verbindung, worin X Stickstoff ist, oder eines pharmazeutisch annehmbaren Säureadditionssalzes der Verbindung der Formel (I) oder des N-Oxids mit einem pharmazeutisch annehmbaren Träger umfaßt.

8. Verfahren nach Anspruch 7, in dem der aktive Bestandteil nach dem in einem der Ansprüche 1 bis 6 beanspruchten Verfahren hergestellt ist.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, IT, LI, LU, NL, SE

1. Composé de formule générale (I) :



où



20

représente un radical hétéroaryle contenant au moins un hétéroatome X choisi dans la classe formée par l'azote, l'oxygène et le soufre et étant facultativement substitué par un ou plusieurs radicaux choisis parmi C₁₋₄-alcoyle, C₁₋₄-alcoxy, amino, C₁₋₄-alcoylamino di(C₁₋₄-alcoyl)amino, halogène, trifluorométhyle, phényle, halophényle, C₁₋₄-alcoylphényle, C₁₋₄-alcoxyphényle, carboxyle, carboxamido, nitro, thiol, C₁₋₄-alcoylthio et C₁₋₄-alcoxycarbonyl; B représente un cycle azabicyclique saturé comprenant 7 à 11 atomes de carbone de cycle et un atome d'azote de cycle qui est séparé de l'atome O de la liaison éther par deux ou trois atomes de carbone de cycle et lorsque l'atome d'azote de cycle n'est pas en position de tête de pont, le N peut être non substitué ou substitué par un radical R' où R' est C₁₋₆-alcoyle, C₃₋₅-alcényle, C₃₋₆-cycloalcoyle, C₃₋₆-cycloalcoyl-C₁₋₂-alcoyle ou aryl- ou hétéroaryl-C₁₋₂-alcoyle (où le radical aryle est un radical phényle ou naphthyle facultativement substitué par un ou plusieurs radicaux halogène, C₁₋₄-alcoxy ou C₁₋₄-alcoyle et le radical hétéroaryle est un radical hétéroaryle mono- ou bicyclique contenant un ou deux hétéroatomes choisis parmi oxygène, azote et soufre) et la partie -OB occupe la position ortho par rapport à l'hétéroatome X; avec la restriction que

30



40

est autre qu'un radical isoquinolinyne substitué ou non substitué et que lorsque B représente un radical quinuclidyle ou tropanyle,



est autre qu'un radical 2-pyridyle substitué ou non substitué; ou un N-oxyde hétéroaromatique du composé où X est azote; ou un sel d'addition d'acide pharmaceutiquement acceptable du composé de formule I ou du N-oxyde.

50


2. Composé suivant la revendication 1, où



est 2-pyridyle facultativement substitué par chloro, nitro, C₁₋₄-alcoyle ou carboxamido, 2- ou 4-pyrimidyle facultativement substitué par chloro, amino, C₁₋₄-alcoxy; 2-pyrazinyle facultativement substitué par halo ou C₁₋₄-alcoyle; 2-pyridazinyle facultativement substitué par halo ou C₁₋₄-alcoxy; 2-quinolylyle facultativement substitué par C₁₋₄-alcoyle; 2-thiényle; 2-benzo(b)thiényle; 1H-indazol-3-yle facultativement substitué par nitro ou C₁₋₄-alcoyle; 2-benzoxazolyle; 2-benzothiazolyle; ou 6-phénanthrinyle.

3. Composé suivant la revendication 1 ou 2, dans laquelle B est :


(a)



(II)


où n est 2, 3 ou 4 et R² est hydrogène ou a la signification attribuée à R¹ dans la revendication 1,

(b)



(III)


(c)



(IV)

où R² a la signification attribuée ci-dessus et m est 1, 2 ou 3 ou

(d)



(V)

où p est 0, 1 ou 2.

4. Composé suivant la revendication 3, dans lequel a est de formule (II) où n est 2 et R² est méthyle.

5. Composé suivant la revendication 1 qui est
l'endo-8-méthyl-3-(2-pyrimidyloxy)-8-azabicyclo[3.2.1]octane

ou

l'endo-8-méthyl-3-(2-quinolyloxy)-8-azabicyclo[3.2.1]octane

ou


l'endo-8-méthyl-3-(2-pyrazinyloxy)-8-azabicyclo[3.2.1]octane

ou


l'endo-3-(6-chloropyridazin-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

- ou
l'endo-3-(6-chloropyrazin-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane
ou
l'endo-3-(benzothiazol-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane
5 ou
l'endo-3-(pyridazin-3-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane
ou
l'éther 2-quinoliny-3-quinuclidinyle
ou
10 l'endo-(phénanthrin-6-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane
ou
l'endo-3-(benzoxazol-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane
ou
l'endo-8-méthyl-3-(3-méthyl-5,6-cyclohexénopyridin-2-yloxy)-8-azabicyclo[3.2.1]octane
15 ou
l'ester éthylique de l'acide endo-2-(8-méthyl-8-azabicyclo[3.2.1]octan-3-yloxy)-5,6-cyclohepténopyridine-3-carboxylique
ou un sel pharmaceutiquement acceptable de l'un de ceux-ci.

- 20 6. Procédé de préparation d'un composé suivant la revendication 1, qui comprend :
(a) la condensation d'un composé de formule



- ou d'un N-oxyde de celui-ci, avec un composé de formule



où



- 40 et B sont tels que définis dans la revendication 1 et l'un d'entre Z et Z' est hydroxyle et l'autre est un radical partant, ou

- (b) le remplacement ou l'élimination d'un substituant sur le radical hétéroaryle ou le cycle azabicyclique d'un composé de formule (I) par des procédés connus dans la spécialité pour former un autre composé de formule I, ou

- 45 (c) l'oxydation d'un composé de formule (I) en le N-oxyde hétéroaromatique de celui-ci, ou

- (d) la conversion d'un composé de formule (I) ou du N-oxyde hétéroaromatique de celui-ci en son sel d'addition d'acide pharmaceutiquement acceptable.

7. Composition pharmaceutique contenant un composé suivant l'une quelconque revendications 1 à 5 en association avec un excipient pharmaceutiquement acceptable.


8. Composé suivant l'une quelconque des revendications 1 à 5 à utiliser comme agent pharmaceutique.

55

Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de préparation d'un composé de formule générale (I) :

5



(I)

10

où

15



20

représente un radical hétéroaryle contenant au moins un hétéroatome X choisi dans la classe formée par l'azote, l'oxygène et le soufre et étant facultativement substitué par un ou plusieurs radicaux choisis parmi C₁₋₄-alcoyle, C₁₋₄-alcoxy, amino, C₁₋₄-alcoylamino, di(C₁₋₄-alcoyl)amino, halogène, trifluorométhyle, phényle, halophényle, C₁₋₄-alcoylphényle, C₁₋₄-alcoxyphényle, carboxyle, carboxamido, nitro, thiol, C₁₋₄-alcoylthio et C₁₋₄-alcoxycarbonyl; B représente un cycle azabicyclique saturé comprenant 7 à 11 atomes de carbone de cycle et un atome d'azote de cycle qui est séparé de l'atome O de la liaison éther par deux ou trois atomes de carbone de cycle et lorsque l'atome d'azote de cycle n'est pas en position de tête de pont, le N peut être non substitué ou substitué par un radical R' où R' est C₁₋₆-alcoyle, C₃₋₅-alcényle, C₃₋₆-cycloalcoyle, C₃₋₆-cycloalcoyl-C₁₋₂-alcoyle ou aryl- ou hétéroaryl-C₁₋₂-alcoyle (où le radical aryle est un radical phényle ou naphthyle facultativement substitué par un ou plusieurs radicaux halogène, C₁₋₄-alcoxy ou C₁₋₄-alcoyle et le radical hétéroaryle est un radical hétéroaryle mono- ou bicyclique contenant un ou deux hétéroatomes choisis parmi oxygène, azote et soufre) et la partie -OB occupe la position ortho par rapport à l'hétéroatome X; avec la restriction que

25

30

35



40

est autre qu'un radical isoquinolinyne substitué ou non substitué et que lorsque B représente un radical quinuclidyle ou tropanyle,

45




50

est autre qu'un radical 2-pyridyle substitué ou non substitué;
ou d'un N-oxyde hétéroaromatique du composé où X est azote;
ou d'un sel d'addition d'acide pharmaceutiquement acceptable du composé de formule I ou du N-oxyde.

qui comprend :

(a) la condensation d'un composé de formule

55



(VI)

ou d'un N-oxyde de celui-ci, avec un composé de formule

Z¹-B (VII)

où



et B sont tels que définis ci-dessus et l'un d'entre Z et Z¹ est hydroxyle et l'autre est un radical partant, ou

(b) le remplacement ou l'élimination d'un substituant sur le radical hétéroaryle ou le cycle azabicyclique d'un composé de formule (I) par des procédés connus dans la spécialité pour former un autre composé de formule I, ou

(c) l'oxydation d'un composé de formule (I) en le N-oxyde hétéroaromatique de celui-ci, ou

(d) la conversion d'un composé de formule (I) ou du N-oxyde hétéroaromatique de celui-ci en son sel d'addition d'acide pharmaceutiquement acceptable.

2. Procédé suivant la revendication 1, qui comprend la condensation d'un procédé de formule (VI) où Z est halogène avec un composé de formule (VII) où Z¹ est hydroxyle.


3. Procédé suivant la revendication 1 ou 2, dans lequel dans le produit,



est 2-pyridyle facultativement substitué par chloro, nitro, C₁₋₄-alcoyle ou carboxamido, 2- ou 4-pyrimidyle facultativement substitué par chloro, amino, C₁₋₄-alcoxy; 2-pyrazinyle facultativement substitué par halo ou C₁₋₄-alcoyle; 2-pyridazinyle facultativement substitué par halo ou C₁₋₄-alcoxy; 2-quinolyle facultativement substitué par C₁₋₄-alcoyle; 2-thiényle; 2-benzo(b)thiényle; 1H-indazol-3-yle facultativement substitué par nitro ou C₁₋₄-alcoyle; 2-benzoxazole; 2-benzothiazole; ou 6-phénanthrinyle.

4. Procédé suivant l'une quelconque des revendications 1 à 3, dans lequel dans le produit B est :


(a)



(II)


où n est 2, 3 ou 4 et R² est hydrogène ou a la signification attribuée à R¹ dans la revendication 1.

(b)




(III)

(c)



(IV)

où R² a la signification attribuée ci-dessus et m est 1, 2 ou 3, ou
(d)



(V)

où p est 0, 1 ou 2.

5. Procédé suivant la revendication 4, dans lequel B est de formule (II) où n est 2 et R² est méthyle.

6. Procédé suivant la revendication 1, dans lequel le produit est l'endo-8-méthyl-3-(2-pyrimidyloxy)-8-azabicyclo[3.2.1]octane

ou l'endo-8-méthyl-3-(2-quinolyloxy)-8-azabicyclo[3.2.1]octane

ou l'endo-8-méthyl-3-(2-pyrazinyloxy)-8-azabicyclo[3.2.1]octane

ou l'endo-3-(6-chloropyridazin-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

ou l'endo-3-(6-chloropyrazin-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

ou l'endo-3-(benzothiazol-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

ou l'endo-3-(pyridazin-3-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

ou l'éther 2-quinolinyl-3-quinuclidinyle

ou l'endo-(phénanthrin-6-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

ou l'endo-3-(benzoxazol-2-yloxy)-8-méthyl-8-azabicyclo[3.2.1]octane

ou l'endo-8-méthyl-3-(3-méthyl-5,6-cyclohexénopyridin-2-yloxy)-8-azabicyclo[3.2.1]octane

ou un sel pharmaceutiquement acceptable de l'un de ceux-ci.

7. Procédé de préparation d'une composition pharmaceutique, qui comprend la mise en association d'un composé de formule générale (I) tel que défini dans la revendication 1 ou d'un N-oxyde hétéroaromatique du composé où X est azote ou d'un sel d'addition d'acide pharmaceutiquement acceptable du composé de formule (I) ou du N-oxyde, avec un excipient pharmaceutiquement acceptable.

8. Procédé suivant la revendication 7 dans lequel le constituant actif est préparé par le procédé suivant l'une quelconque des revendications 1 à 6.